A new therapeutic antibody masks ErbB2 to its partners.

Badache A; Hynes NE

首页> 外文期刊>Cancer Cell >A new therapeutic antibody masks ErbB2 to its partners.

【24h】

A new therapeutic antibody masks ErbB2 to its partners.

机译：一种新的治疗性抗体为其合作伙伴掩盖了ErbB2。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In cancer cells, the ErbB2 receptor tyrosine kinase can be activated in two ways: by overexpression or by ligand-mediated stimulation of another ErbB receptor. The ErbB2-targeting antibody trastuzumab (Herceptin) is used for treatment of metastatic breast cancer patients whose tumors overexpress ErbB2. A new structural study in this issue of Cancer Cell reveals how targeting ErbB2 with another antibody, pertuzumab (Omnitarg), prevents ligand-induced dimerization of ErbB2 with the other ErbB receptors. Pertuzumab's novel mode of action might offer additional therapeutic opportunities for treatment of tumors expressing ligand-activated ErbB2.

机译：在癌细胞中，ErbB2受体酪氨酸激酶可以通过两种方式激活：通过过度表达或通过配体介导的另一种ErbB受体的刺激。靶向ErbB2的抗体曲妥珠单抗（赫赛汀）用于治疗肿瘤过度表达ErbB2的转移性乳腺癌患者。在本期《癌细胞》杂志上的一项新的结构研究表明，用另一种抗体Pertuzumab（Omnitarg）靶向ErbB2可以防止配体诱导的ErbB2与其他ErbB受体的二聚化。帕妥珠单抗的新颖作用方式可能为表达表达配体激活的ErbB2的肿瘤提供额外的治疗机会。

著录项

来源
《Cancer Cell》 |2004年第4期|共3页
作者
Badache A; Hynes NE;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Antibodies; receptor; Therapeutic; Ligands; activate; 抗体; 配体;

机译：Antibodies;receptor;Therapeutic;Ligands;activate;抗体;配体;

相似文献

外文文献
中文文献
专利

1. A new therapeutic antibody masks ErbB2 to its partners. [J] . Badache A, Hynes NE Cancer Cell . 2004,第4期

机译：一种新的治疗性抗体为其合作伙伴掩盖了ErbB2。
2. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. [J] . Rolla S, Ria F, Occhipinti S, The Journal of Immunology: Official Journal of the American Association of Immunologists . 2010,第11期

机译：结合调节性T细胞缺失的Erbb2 DNA疫苗可增强抗体反应，并揭示潜在的低存活性T细胞：潜力和治疗功效的局限性。
3. Erbb2 DNA Vaccine Combined with Regulatory T Cell Deletion Enhances Antibody Response and Reveals Latent Low-Avidity T Cells: Potential and Limits of Its Therapeutic Efficacy [J] . Simona Rolla, Francesco Ria, Sergio Occhipinti, The journal of immunology . 2010,第11期

机译：Erbb2 DNA疫苗结合调节性T细胞缺失增强抗体反应并揭示潜在的低亲和力T细胞：潜力和治疗功效的局限性
4. Non-fucosylated Therapeutic Antibodies: The Next Generation of Therapeutic Antibodies [C] . Mitsuo Satoh, Shigeru Iida, Naoko Yamane-Ohnuki, Annual Meeting of the Japanese Association for Animal Cell Technology . 2009

机译：非岩氧化治疗抗体：下一代治疗抗体
5. Antigenized Antibody as a Novel Technology Platform for Developing Therapeutic Anti-GPCR Antibodies. [D] . Chen, Lei. 2017

机译：抗原化抗体是开发治疗性抗GPCR抗体的新型技术平台。
6. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab [O] . Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, -1

机译：ERBB2信号传导的激活导致抗EGFR定向治疗抗体的甲嘧胍酮
7. A new therapeutic antibody masks ErbB2 to its partners [O] . Badache Ali, Hynes Nancy E 2004

机译：一种新型治疗性抗体为其合作伙伴掩盖了ErbB2

A new therapeutic antibody masks ErbB2 to its partners.

摘要

著录项

相似文献

相关主题

期刊订阅